Ranbaxy Laboratories and its new owner Japan’s Daiichi Sankyo, which now holds 63.92% of Ranbaxy’s equity share capital, reconstituted a new 10-member panel.

From the company’s earlier 15 member panel, the company retained only three members including former owner Malvinder Singh, COO Atul Sobti and Religare CEO & MD Sunil Godhwani.

The newly announced board reflects the changed ownership structure at Ranbaxy, following Daiichi Sankyo’s strategic investment during the last month (Nov 2008).

Aurobindo Pharma, a leading drug manufacturer, has announced that it has got tentative sanction from the US Food and Drug Administration (USFDA) for PerindopriL Erbumine tablets.

The approval has been granted for 2 mg, 4 mg and 8 mg dosage of drug.

According to the sources, PerindopriL Erbumine tablets are indicated for the treatment of high blood pressure.  
 
The sources further revealed that the conglomerate has also received tentative approval for Escitalopram Oxalat Oral solution 5 mg base/5 ml.  

Ranbaxy Laboratories Ltd, a leading pharmaceutical major, has announced that it has clinched an exclusive licensing pact with US-based BioPro Pharmaceutical to market Gliadel tablets in India.

Earlier, Ranbaxy had announced a similar agreement with CD Pharma, a leading Europe-based  biotech  firm to sell its probiotic dental medicine Inersan in India and  Nepal.

Plethico Pharma to Take Over 20% stake in Tricon Holdings arm for $20 mn

A global pharma company with a strong emphasis on herbal and neutralceutical segments, Plethico Pharmaceuticals Ltd, is all set to acquire 20% stake in the Sputnik Regional Aptika Holdings Ltd, a drug retailer in the Commonwealth of Independent States, or CIS, from Hong Kong-based Tricon Holdings Ltd for $20 million (Rs100 crore).

Novartis, a leading Switzerland based multinational pharma company, has informed that it has linked up with USV, a leading healthcare company to sell its anti- diabetic product Galvus in India.

According to the sources, the tie up with USV is a part of Novartis plans to pitch its proposed product against Merck's Januvia by pricing it lower - in the Indian anti-diabetic market which saw total sales of Rs 1,672 crore till June 2008.